A Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of ABBV-181 (Budigalimab) in Adult Participants With Human Immunodeficiency Virus (HIV)-1

Brief summary

This study will be conducted in two stages and will test the safety/tolerability, pharmacokinetics (how the body handles study drug) and pharmacodynamics (effects on the immune system and the virus) of the study drug ABBV-181 in Human immunodeficiency virus (HIV)-1 infected participants undergoing Antiretroviral therapy (ART) interruption.

Interventional study

Human Immunodeficiency Virus (HIV)
HIV Infection
41 patients
  • 1
  • 2
  • 3
  • 4
Protocol ID:
Intervention model:
Parallel Assignment
Triple (Participant, Care Provider, Investigator)


Eligibility criteria

Participant attributes:
Male and Female


From 18 Years to 65 Years.

Inclusion Criteria:

- Body Mass Index (BMI) between 18.0 and 35 kg/m2.

- HIV-1 infected on antiretroviral therapy (ART) for at least 12 months prior to
screening and on current ART regimen for at least 8 weeks prior to screening.

- Meets HIV-specific laboratory parameters as below:

- Plasma HIV-1 RNA below lower limit of quantification (LLOQ) at screening and at
least 6 months prior to screening.

- CD4+ T cell count >= 500 cells/uL at screening and at least once during the 12
months prior to screening.

- CD4+ T cell nadir of >= 200 cells/uL during chronic infection.

- Willing to undergo ART interruption.

- Agrees to use an effective barrier method of protection (male and/or female condoms)
during sexual activity for protection against HIV-1 transmission throughout the entire

Exclusion Criteria:

- Known resistance to at least 2 classes of ART.

- History of AIDS-defining illness.

- Active or suspected malignancy or history of malignancy (other than basal cell skin
cancer or cervical carcinoma in situ) in the past 5 years.

- History of or active immunodeficiency (other than HIV).

- Active autoimmune disease or history of autoimmune disease that has required systemic

- Prior receipt of immunomodulatory or immunosuppressive (including intravenous infusion
or oral steroids at any dose, but excluding steroids that are inhaled, topical or by
local injection) therapy within 24 weeks prior to the first dose of study drug.

- Prior therapy/exposure to ABBV-181 or any other immune checkpoint inhibitor.

- Current hepatitis B virus or hepatitis C virus infection.

- Clinically significant medical disorders that might expose the participants to undue
risk of harm, confound study outcomes, or prevent the participant from completing the
study (including but not limited to significant or unstable cardiac, neurologic or
pulmonary disease, chronic active infectious disease except for HIV, chronic liver
disease, poorly controlled diabetes mellitus and history of Stevens Johnson Syndrome
toxic epidermal necrolysis (TEN), or drug reaction with eosinophilia and systemic
symptoms (DRESS)).

- Known psychiatric or substance abuse disorders that would interfere with adherence to
study requirements.

- Female participants must not be pregnant, breastfeeding, or considering becoming
pregnant during the study.

All the cities where the clinical studies are located

Ottawa - K1H 8L6
Toronto - M5G 2C4
Montreal - H2X 2P4


More information about this study